These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34670036)

  • 1. Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents.
    Reis BY; Barda N; Leshchinsky M; Kepten E; Hernán MA; Lipsitch M; Dagan N; Balicer RD
    N Engl J Med; 2021 Nov; 385(22):2101-2103. PubMed ID: 34670036
    [No Abstract]   [Full Text] [Related]  

  • 2. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
    Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel.
    Munitz A; Yechezkel M; Dickstein Y; Yamin D; Gerlic M
    Cell Rep Med; 2021 May; 2(5):100264. PubMed ID: 33899031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waning Immunity after the BNT162b2 Vaccine in Israel.
    Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Freedman L; Haas EJ; Milo R; Alroy-Preis S; Ash N; Huppert A
    N Engl J Med; 2021 Dec; 385(24):e85. PubMed ID: 34706170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
    Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
    Dickerman BA; Gerlovin H; Madenci AL; Kurgansky KE; Ferolito BR; Figueroa Muñiz MJ; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA
    N Engl J Med; 2022 Jan; 386(2):105-115. PubMed ID: 34942066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel.
    Prunas O; Warren JL; Crawford FW; Gazit S; Patalon T; Weinberger DM; Pitzer VE
    Science; 2022 Mar; 375(6585):1151-1154. PubMed ID: 35084937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel.
    Muhsen K; Maimon N; Mizrahi A; Varticovschi B; Bodenheimer O; Gelbshtein U; Grotto I; Cohen D; Dagan R
    N Engl J Med; 2022 Jan; 386(4):399-401. PubMed ID: 34936758
    [No Abstract]   [Full Text] [Related]  

  • 9. Audio Interview: Waning Immunity against SARS-CoV-2.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(24):e99. PubMed ID: 34879456
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Bertollini R;
    N Engl J Med; 2022 Feb; 386(8):799-800. PubMed ID: 35045222
    [No Abstract]   [Full Text] [Related]  

  • 11. BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years.
    Jang EJ; Choe YJ; Kim RK; Park YJ
    JAMA Pediatr; 2023 Mar; 177(3):319-320. PubMed ID: 36622683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant.
    Sheikh A; Robertson C; Taylor B
    N Engl J Med; 2021 Dec; 385(23):2195-2197. PubMed ID: 34670038
    [No Abstract]   [Full Text] [Related]  

  • 13. Protection against Covid-19 by BNT162b2 Booster across Age Groups.
    Bar-On YM; Goldberg Y; Mandel M; Bodenheimer O; Freedman L; Alroy-Preis S; Ash N; Huppert A; Milo R
    N Engl J Med; 2021 Dec; 385(26):2421-2430. PubMed ID: 34879188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021.
    Glatman-Freedman A; Hershkovitz Y; Kaufman Z; Dichtiar R; Keinan-Boker L; Bromberg M
    Emerg Infect Dis; 2021 Nov; 27(11):2919-2922. PubMed ID: 34570694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNT162b2 Vaccine Booster and Mortality Due to Covid-19.
    Arbel R; Hammerman A; Sergienko R; Friger M; Peretz A; Netzer D; Yaron S
    N Engl J Med; 2021 Dec; 385(26):2413-2420. PubMed ID: 34879190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.
    Collie S; Champion J; Moultrie H; Bekker LG; Gray G
    N Engl J Med; 2022 Feb; 386(5):494-496. PubMed ID: 34965358
    [No Abstract]   [Full Text] [Related]  

  • 17. Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France.
    Lefèvre B; Tondeur L; Madec Y; Grant R; Lina B; van der Werf S; Rabaud C; Fontanet A
    Lancet Healthy Longev; 2021 Nov; 2(11):e685-e687. PubMed ID: 34580665
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.
    Gray G; Collie S; Goga A; Garrett N; Champion J; Seocharan I; Bamford L; Moultrie H; Bekker LG
    N Engl J Med; 2022 Jun; 386(23):2243-2245. PubMed ID: 35507482
    [No Abstract]   [Full Text] [Related]  

  • 19. Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine.
    Amir O; Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Ash N; Alroy-Preis S; Huppert A; Milo R
    Nat Commun; 2022 Apr; 13(1):1971. PubMed ID: 35418201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.
    Mileto D; Fenizia C; Cutrera M; Gagliardi G; Gigantiello A; De Silvestri A; Rizzo A; Mancon A; Bianchi M; De Poli F; Cuomo M; Burgo I; Longo M; Rimoldi SG; Pagani C; Grosso S; Micheli V; Rizzardini G; Grande R; Biasin M; Gismondo MR; Lombardi A
    Emerg Microbes Infect; 2021 Dec; 10(1):2235-2243. PubMed ID: 34749573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.